Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Fineline Cube Apr 29, 2026
Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Fineline Cube Apr 29, 2026
Company Deals Medical Device

NAMSA to Acquire WuXi AppTec’s US Medical Device Testing Business

Fineline Cube Jan 20, 2025

US-based medical device contract research organization (CRO) NAMSA is set to acquire the medical device...

Company Drug

MHRA Approves Gilead’s Livdelzi for Primary Biliary Cholangitis

Fineline Cube Jan 20, 2025

The Medicines and Healthcare products Regulatory Agency (MHRA) last week signed off on US-based Gilead...

Policy / Regulatory

Tianjin Healthcare Official Gao Xue Under Investigation

Fineline Cube Jan 20, 2025

Gao Xue, director of the National High-value Medical Consumables Joint Procurement Office, member of the...

Medical Device Policy / Regulatory

US BIS Imposes Export Controls on Biotech Lab Instruments

Fineline Cube Jan 20, 2025

The Department of Commerce’s Bureau of Industry and Security (BIS) of the United States last...

Company

Junshi Biosciences Forecasts 29.71% Revenue Growth for 2024

Fineline Cube Jan 20, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has released its 2024 annual...

Company Drug

FDA Clears Amgen’s Lumakras and Vectibix Combo for KRAS G12C-mutated mCRC

Fineline Cube Jan 20, 2025

US-based Amgen (NASDAQ: AMGN) has announced receiving clearance from the US Food and Drug Administration...

Company Drug

Luye Pharma Launches Erzofri in US Market

Fineline Cube Jan 20, 2025

China-based Luye Pharma Group (HKG: 2186) has announced the initiation of commercialization of its in-house...

Company Drug

Novo Nordisk’s Semaglutide 7.2 mg Shows Superior Weight Loss in Phase III Study

Fineline Cube Jan 20, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced positive headline results from the Phase III...

Company Deals

Xinzeyuan Medical Raises Series B+ Funding for Surgical Supply Chain

Fineline Cube Jan 20, 2025

Xinzeyuan Medical Technology Co., Ltd, a minimally invasive surgical supply chain platform enterprise based in...

Company Drug

Zai Lab’s KarXT NDA Accepted by NMPA for Schizophrenia Treatment

Fineline Cube Jan 20, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that a New Drug...

Company Drug

Frontier Biotechnologies Gains NMPA Approval for Albuvirtide Phase II Study

Fineline Cube Jan 20, 2025

Nanjing-based Frontier Biotechnologies Inc. has announced receiving approval from the National Medical Products Administration (NMPA)...

Company Drug

Wanbangde’s Huperzine A Receives FDA Clearance for HIE Study

Fineline Cube Jan 20, 2025

China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced receiving clearance from the...

Company Drug

FDA Approves Datroway for HR+/HER2- Breast Cancer Treatment

Fineline Cube Jan 20, 2025

Datroway (datopotamab deruxtecan-dlnk, Dato-Dxd), a Trop-2-directed antibody and topoisomerase inhibitor conjugate co-developed by Japan-based Daiichi...

Company Drug

Allist Pharmaceuticals Gains NMPA Approval for Furmonertinib Clinical Study

Fineline Cube Jan 20, 2025

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd has announced receiving approval from the National Medical Products...

Policy / Regulatory

NHSA Seeks Expert Opinions on VBP Drug Quality and Efficacy

Fineline Cube Jan 20, 2025

The National Healthcare Security Administration (NHSA) has released a letter titled “Letter on Requesting Assistance...

Company Drug

Junshi Biosciences’ Toripalimab Gains TGA Approval for Nasopharyngeal Carcinoma

Fineline Cube Jan 20, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval...

Company

Inscinstech Secures C-Series Financing for Biopharma Expansion

Fineline Cube Jan 19, 2025

Inscinstech Co., Ltd., a leading intelligent technology company based in Suzhou, has successfully completed a...

Company

Raytone Bio Completes Angel Round to Advance iSus® Platform

Fineline Cube Jan 18, 2025

Raytone Bio, a Shenzhen-based biopharmaceutical company, has announced the completion of a multi-million RMB Angel...

Company Drug

Aosaikang’s Limertinib Approved for EGFR T790M-Mutated NSCLC

Fineline Cube Jan 18, 2025

Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharm, SHE: 002755) has recently received approval from the...

Company Drug

Johnson & Johnson Submits NDA for TAR-200 in High-Risk Bladder Cancer

Fineline Cube Jan 17, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced the initiation of the submission of...

Posts pagination

1 … 217 218 219 … 659

Recent updates

  • Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed
  • Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion
  • Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement
  • Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets
  • Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed

Company

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion

Company

Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.